Akeso Inc represents values of innovation, integrity, and patient-centricity in the pharmaceutical industry. With a strong commitment to advancing healthcare, Akeso Inc focuses on discovering and developing innovative therapies that address unmet medical needs. The company's corporate philosophy emphasizes the highest standards of ethics, transparency, and social responsibility. Akeso Inc strives to improve patient outcomes through rigorous research, collaboration, and a dedication to delivering effective and affordable treatments. By prioritizing innovation and patient well-being, Akeso Inc establishes itself as a trusted leader in the pharmaceutical sector.

Akeso Inc is primarily present in China.

Akeso Inc, a leading biopharmaceutical company, has achieved numerous significant milestones in its journey. Notably, the company successfully completed its initial public offering (IPO) in 2020, representing a major step in attracting investment and expanding its financial capabilities. Akeso Inc has also made significant progress in advancing its innovative pipeline of therapeutics, including breakthrough research and development in the fields of oncology and autoimmune diseases. Moreover, the company has forged strategic partnerships with renowned global pharmaceutical companies, enabling access to new markets and potential collaborations. These achievements highlight Akeso Inc's commitment to pioneering medical advancements and ensuring a promising future.

Akeso Inc is a leading biotechnology company specializing in the research and development of innovative therapies for various diseases. Founded in 2012, Akeso Inc has a strong focus on antibody-based therapies and has successfully developed several breakthrough drugs. The company's dedication to scientific excellence and commitment to improving patient outcomes has propelled its rapid growth in the pharmaceutical industry. With a strong emphasis on research and development, Akeso Inc aims to address unmet medical needs and make a significant impact on global healthcare.

The main competitors of Akeso Inc in the market include companies such as XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics.

Akeso Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Akeso Inc. is focused on developing innovative biopharmaceutical products for the treatment of major diseases. Akeso Inc. aims to address unmet medical needs by researching and developing cutting-edge therapies, particularly in the areas of oncology, autoimmune diseases, and metabolic disorders. With a strong emphasis on scientific advancement and clinical development, Akeso Inc. strives to bring novel and effective treatment options to patients worldwide. By leveraging its expertise in drug discovery and strategic partnerships, Akeso Inc. is committed to improving global healthcare outcomes and driving sustainable growth in the pharmaceutical industry.

Akeso KGV ir -73,65.

Akeso KUV ir 11,38.

AlleAktien kvalitātes vērtējums Akeso ir 2/10.

gaidāmā Akeso apgrozījums ir 2,69 miljardi CNY.

gaidāmā Akeso peļņa ir -415,68 milj. CNY.

Akeso Inc is a biotechnology company specializing in the research and development of novel therapies for complex diseases such as cancer, neurodegenerative diseases, and infections. The company was founded in 2016 and is headquartered in San Diego, California. The business model of Akeso Inc is based on the research and development of new therapies using state-of-the-art technology platforms to identify novel drug candidates. The goal is to identify disease-specific targets and develop drugs that target these specific targets to achieve optimal efficacy and tolerability. Akeso Inc has several business areas, which will be further explained below. 1. Drug Discovery: Akeso Inc utilizes advanced technology platforms such as high-throughput screening (HTS) or DNA sequencing to identify new drug candidates. Promising therapy options are discovered and selected through an extensive library of chemical compounds and sophisticated analytics. 2. Research and Development: After identifying drug candidates, the research and development phase begins. Both preclinical and clinical studies are conducted to test the efficacy and tolerability of the therapeutics. 3. Partnerships: Akeso Inc collaborates with various pharmaceutical companies and academic partners to jointly realize research and development projects and bring therapeutic drugs to the market. 4. Business Development: Akeso Inc is seeking strategic business opportunities to diversify its resources. This includes acquisitions, partnerships, and licensing agreements with other companies. Akeso Inc also offers products that range from research and development to the distribution of therapeutics. For example, the company has a library of several million chemical compounds that can be used to identify drug candidates. Additionally, Akeso Inc provides support for preclinical and clinical development of therapeutic options. Overall, the business model of Akeso Inc is based on identifying new therapy options for diseases where effective treatments are not yet available. Through collaboration with various partners and the use of cutting-edge technology platforms, the company aims to bring groundbreaking therapeutic options to the market.

Akeso izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Akeso vai uzņēmums nedod dividendes.

Akeso ISIN ir KYG0146B1032.

Akeso WKN ir A2P200.

Akeso simbols ir 9926.HK.

Pēdējo 12 mēnešu laikā Akeso maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Akeso plāno maksāt dividendes 0 CNY apmērā.

Akeso pašreizējā dividendu rentabilitāte ir .

Akeso maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Akeso pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

Akeso tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Akeso apmērā 0 CNY, kas tika izmaksāta 17.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.07.2024..

Pēdējās dividendes izmaksa notika 17.07.2024..

Gadā 2023, Akeso izmaksāja 0 CNY dividendes.

Akeso dividendes tiek izmaksātas CNY.